Latest Capital Raise News

Latrobe Magnesium Limited has addressed ASX concerns over recent share price and volume spikes, attributing the market activity to recognition of its asset value and the imminent start of its demonstration plant.

Meteoric Resources has successfully raised $42.5 million through an oversubscribed placement, underpinning its push towards a Final Investment Decision for the Caldeira Rare Earth Project in 2026.

IperionX has secured A$70 million through a share placement to fast-track expansion of its titanium production capacity in the U.S., aligning closely with Department of Defense priorities.

Cygnus Metals reports standout drilling results at its Chibougamau project, highlighting the new Golden Eye prospect and Corner Bay deposit, supported by a strong A$18.3 million capital raise to accelerate development.

Macarthur Minerals has updated its rights issue prospectus, introducing a cap on the underwriter's shareholding and revising key offer terms. These changes aim to balance funding needs with shareholder control and regulatory compliance.

NeuroScientific Biopharmaceuticals has completed its acquisition of StemSmart technology, reporting promising clinical results in Crohn’s disease and GVHD, alongside a $3.5 million capital raise to fuel next-stage development.

Elsight Limited has raised A$60 million through a strongly supported placement, marking a milestone with consecutive record revenues and cash flow breakeven. The company is poised to capitalize on surging defence budgets and expanding drone markets with a robust pipeline of opportunities.

Elsight Limited reports a record 340% revenue surge to US$4.8 million in the first half of 2025, backed by a robust US$11.45 million contract backlog and a strategic A$60 million capital raise to fuel expansion.

AdAlta Limited has prioritized two promising CAR-T cellular immunotherapy products for licensing agreements and successfully raised $1.3 million to support its strategic expansion. The company’s focused capital management and pipeline refinement signal a pivotal phase in its ‘East to West’ strategy.

Tetratherix Limited has marked a pivotal quarter with a $25 million ASX listing, an exclusive licensing agreement with Bio Optix for ophthalmic devices, and progress on FDA regulatory submissions for its prostate spacer product.

Alligator Energy reports a 10% increase in indicated uranium resources at its Samphire Project, secures a $17.25 million capital raise, and announces a CEO transition as it advances key uranium exploration and development milestones.

Race Oncology has safely treated the first patient with its RC220 drug alone and in combination with doxorubicin in a Phase 1 trial, while bolstering its clinical leadership and maintaining a strong cash position to fund operations through 2026.